Gan & Lee Pharmaceuticals.
603087
Kedudukan dalam Saham
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Harga Saham
$10.03
Modal Pasaran
$5.99B
Perubahan (1 hari)
-3.71%
Perubahan (1 tahun)
2.30%
Negara
CN
Perdagangan Gan & Lee Pharmaceuticals. (603087)
Kategori
Healthcare
Pendapatan untuk Gan & Lee Pharmaceuticals. (603087)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Gan & Lee Pharmaceuticals., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Gan & Lee Pharmaceuticals. dari 2013 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2025 | $175.78M | 103.53% |
| 2024 | $86.36M | 99.69% |
| 2023 | $43.25M | -151.22% |
| 2022 | $-84.44M | -131.65% |
| 2021 | $266.84M | 20.60% |
| 2020 | $221.27M | 10.25% |
| 2019 | $200.69M | 23.97% |
| 2018 | $161.88M | -16.93% |
| 2017 | $194.88M | 49.21% |
| 2016 | $130.61M | 61.32% |
| 2015 | $80.96M | 41.18% |
| 2014 | $57.35M | 44.07% |
| 2013 | $39.81M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $3.62B | - |
US
|
|
| $4.11B | - |
FR
|
|
| - | - |
JP
|
|
| $1.59B | - |
US
|
|
| - | - |
CH
|
